BMS International

Bristol Myers Squibb is a premier global biopharmaceutical company dedicated to the discovery and development of innovative medicines for serious diseases. The company holds a dominant position in oncology and hematology, bolstered by the landmark acquisition of Celgene, and maintains a leading cardiovascular franchise through its partnership on Eliquis. BMS is actively diversifying its portfolio into immunology and neuroscience while expanding its technological capabilities in cell therapy and targeted protein degradation. With a robust late-stage pipeline and a focus on precision medicine, the company continues to address significant unmet needs in chronic and life-threatening conditions.